1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Neoplasms in 8 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All 21 drugs are orally bioavailable or topically effective." | 3.01 | Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States. ( Roskoski, R, 2023) |
| "Thus, we identify a cancer driver paradigm and a precision medicine approach for selective targeting of human malignancies driven by TEAD/YAP transcription through mechanisms that either upregulate or depend on homeostatic RhoA mechano-signaling." | 1.72 | ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation. ( Aaronson, SA; Bai, Y; Esposito, D; Jin, J; Pant, I; Poulikakos, PI; Qiao, RF; Shen, Y; Yang, X, 2022) |
| "A synthetic lethal effect arises when a cancer-associated change introduces a unique vulnerability to cancer cells that makes them unusually susceptible to a drug's inhibitory activity." | 1.62 | A high-content screen identifies the vulnerability of MYC-overexpressing cells to dimethylfasudil. ( Allen, TD; Shi, Q; Yang, D; You, F; Zhang, J; Zhang, S, 2021) |
| "Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS." | 1.38 | STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. ( Carr, SA; Fröhling, S; Golub, TR; Jaffe, JD; Luo, T; Masson, K; Ross, NT; Scherer, CA; Scholl, C; Schreiber, SL; Silkworth, W; Stern, AM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Esposito, D | 1 |
| Pant, I | 1 |
| Shen, Y | 1 |
| Qiao, RF | 1 |
| Yang, X | 1 |
| Bai, Y | 1 |
| Jin, J | 1 |
| Poulikakos, PI | 1 |
| Aaronson, SA | 1 |
| Roskoski, R | 1 |
| Zhang, J | 1 |
| Zhang, S | 1 |
| Shi, Q | 1 |
| Allen, TD | 1 |
| You, F | 1 |
| Yang, D | 1 |
| Lu, Q | 1 |
| Longo, FM | 1 |
| Zhou, H | 1 |
| Massa, SM | 1 |
| Chen, YH | 1 |
| Iorio, F | 1 |
| Bosotti, R | 1 |
| Scacheri, E | 1 |
| Belcastro, V | 1 |
| Mithbaokar, P | 1 |
| Ferriero, R | 1 |
| Murino, L | 1 |
| Tagliaferri, R | 1 |
| Brunetti-Pierri, N | 1 |
| Isacchi, A | 1 |
| di Bernardo, D | 1 |
| Luo, T | 1 |
| Masson, K | 1 |
| Jaffe, JD | 1 |
| Silkworth, W | 1 |
| Ross, NT | 1 |
| Scherer, CA | 1 |
| Scholl, C | 1 |
| Fröhling, S | 1 |
| Carr, SA | 1 |
| Stern, AM | 1 |
| Schreiber, SL | 1 |
| Golub, TR | 1 |
| Hakomori, S | 1 |
| Whalen, MM | 1 |
| Green, CB | 1 |
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Neoplasms
| Article | Year |
|---|---|
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Humans; Neoplasms; Protein Kin | 2023 |
7 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Neoplasms
| Article | Year |
|---|---|
ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Cycle Proteins; Cell Line, Tumor; Femal | 2022 |
A high-content screen identifies the vulnerability of MYC-overexpressing cells to dimethylfasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Cell Line, Tumor; Humans; Neop | 2021 |
Signaling through Rho GTPase pathway as viable drug target.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Aminoquinolines; Anilides; Animals; Benzamide | 2009 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blottin | 2010 |
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Biological Assay; Biomarkers, Tumor; Cell Line, Tumor | 2012 |
Novel endothelial cell activation factor(s) released from activated platelets which induce E-selectin expression and tumor cell adhesion to endothelial cells: a preliminary note.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Animals; Biological Factors; Cell Adhesion | 1994 |
Lysis-sensitive targets stimulate an elevation of cAMP in human natural killer cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Alkal | 1998 |